{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/","result":{"data":{"firstChapter":{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field a435d0e0-285e-4dea-9fc7-abf6326388d6 --><h1>Chronic obstructive pulmonary disease - Summary</h1><!-- end field a435d0e0-285e-4dea-9fc7-abf6326388d6 -->","htmlStringContent":"<!-- begin item 22e502e8-364f-4fca-ae93-27ac9d6f82b9 --><!-- begin field bdc90f48-cbde-4e92-b783-4a4c0dc445ed --><ul><li>Chronic obstructive pulmonary disease (COPD) is a common, treatable (but not curable) and largely preventable lung condition.<ul><li>It is characterised by persistent respiratory symptoms and airflow obstruction which is usually progressive and not fully reversible.</li></ul></li><li>Tobacco smoking is a major risk factor for the development of COPD.</li><li>Complications include reduced quality of life and increased morbidity and mortality.</li><li>Diagnosis of COPD is based on the presence of typical clinical features supported by spirometry.<ul><li>COPD should be suspected in people aged over 35 years, who have a risk factor and symptoms including exertional breathlessness, chronic/recurrent cough, or regular sputum production.</li><li>A post bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) of less than 0.7 on spirometry confirms persistent airflow obstruction.</li><li>Investigations (including chest X-ray and full blood count) should be arranged to exclude other causes of symptoms.</li></ul></li><li>Once diagnosed, all people with COPD should be offered:<ul><li>Information on the condition and risk factors for progression.</li><li>Smoking cessation treatment and support (where applicable).</li><li>Pneumococcal and influenza vaccination.</li><li>Pulmonary rehabilitation (where applicable).</li><li>Treatment for associated comorbidities (such as anxiety and depression).</li><li>A self-management plan.</li></ul></li><li>As initial inhaled therapy for COPD, a short-acting bronchodilator (SABA), or short-acting muscarinic antagonist (SAMA) for use as needed (to relieve breathlessness and improve exercise tolerance) should be offered.<ul><li>If symptoms are not controlled, long-acting bronchodilators (LABAs), long-acting muscarinic antagonists (LAMAs), or inhaled corticosteroids (ICSs), and add on therapies may be considered in a stepwise approach — choice of treatment depends on the specific clinical situation.</li><li>ICSs should be prescribed in combination with a long-acting bronchodilator and are associated with an increased risk of pneumonia.</li></ul></li><li>Referral to a respiratory specialist is indicated if:<ul><li>Lung cancer, cor pulmonale, or bronchiectasis is suspected.</li><li>COPD is very severe or rapidly worsening.</li><li>The person is under 40 years of age and/or there is a family history of alpha-1-antitrypsin deficiency.</li><li>There is diagnostic uncertainty.</li><li>Oxygen therapy, long-term non-invasive ventilation therapy, long-term oral corticosteroids or lung surgery is being considered.</li></ul></li><li>Referral for pulmonary rehabilitation is indicated if the person:<ul><li>Is functionally disabled by COPD.</li><li>Has had a recent hospitalization for an acute exacerbation.</li></ul></li><li>Emergency admission should be considered for people with an acute exacerbation of COPD who have:<ul><li>Severe breathlessness.</li><li>Inability to cope at home (or living alone).</li><li>Poor or deteriorating general condition.</li><li>Acute confusion or impaired consciousness.</li><li>Cyanosis or reduced oxygen saturation.</li><li>Worsening peripheral oedema.</li><li>A new arrhythmia.</li></ul></li><li>Treatment of acute exacerbations not requiring admission involves:<ul><li>Advising the person to increase the dose or frequency of short-acting bronchodilators.</li><li>Considering the need for oral corticosteroids and an antibiotic.</li><li>Advising the person when to seek medical help and reassessing them if symptoms worsen rapidly or significantly at any time.</li></ul></li><li>All people with COPD should be followed up; the frequency depending on the severity of symptoms.</li><li>End-of-life issues should be discussed when appropriate and advance care planning offered.</li></ul><!-- end field bdc90f48-cbde-4e92-b783-4a4c0dc445ed --><!-- end item 22e502e8-364f-4fca-ae93-27ac9d6f82b9 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","aliases":[],"chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","slug":"management","fullItemName":"Management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","aliases":[],"topicSummary":"Chronic obstructive pulmonary disease (COPD) is a treatable (but not curable) and largely preventable lung disease.","lastRevised":"Last revised in October 2020","nextPlannedReviewBy":"2024-01-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2024-01","nextPlannedReviewByDisplay":"January 2024","specialities":[{"id":"164e61aa-02a9-5edf-9943-5d891add3a7f","name":"Respiratory","slug":"respiratory"}],"chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","slug":"management","fullItemName":"Management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f"}},"staticQueryHashes":["3666801979"]}